Paper Details

  1. Home
  2. Paper Details

Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.

Author: BangherM, Bosch-NicolauP, Correa-OliveiraR, EloiS, FernándezM L, MolinaI, Molina-MorantD, RibeiroA L P, SalvadorF, Sanchez-MontalvaA, Sosa-EstaniS, SulleiroE, VillarJ C, de PaulaA M B

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Chagas disease (CD) is a serious infection that affects many people worldwide. While benznidazole (BNZ) is the main drug used for treatment, its effectiveness is limited, especially in adults. The current recommended dosage is based on studies that weren't rigorously designed, and the optimal dose of BNZ hasn't been thoroughly tested in clinical trials.
Paper Details　
Original Abstract of the Article :
Chagas disease (CD) continues to be a neglected infectious disease with one of the largest burdens globally. Despite the modest cure rates in adult chronic patients and its safety profile, benznidazole (BNZ) is still the drug of choice. Its current recommended dose is based on nonrandomized studies,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158046/

データ提供：米国国立医学図書館（NLM）

Finding the Right Dose of Benznidazole for Chagas Disease

Imagine a vast desert plagued by a hidden, persistent enemy - the Chagas disease parasite. This research focuses on finding the optimal dose of [benznidazole (BNZ)], a crucial weapon in our fight against this parasitic infection. The researchers use a [multicenter randomized Phase II non-inferiority clinical trial] to analyze the efficacy and safety of different dosages of BNZ in adults with chronic Chagas disease. The goal is to find the right balance - enough to combat the parasite effectively but not too much to cause unnecessary harm. The research team is like a caravan traversing the desert, meticulously searching for the right path and resources to overcome this challenging foe.

Optimizing Treatment for Chronic Chagas Disease

The research indicates that the current recommended dose of BNZ may not be the most effective. This highlights the need for further research to determine the optimal dose for different stages and types of Chagas disease. The researchers' efforts are like finding a hidden oasis of knowledge, providing valuable insights into the best treatment options for patients.

Improving Treatment Outcomes for Chagas Disease

The results of this research could significantly improve the lives of patients with Chagas disease. Finding the optimal dose of BNZ will lead to more effective treatments, potentially reducing the long-term health complications associated with this neglected disease. The research team's work is like a beacon of hope in the desert, guiding us towards better treatment options and a brighter future for those affected.

Dr.Camel's Conclusion

This research represents a vital step towards improving the lives of those affected by Chagas disease. Finding the optimal dose of BNZ is like finding the perfect balance between the harsh realities of the desert and the promise of a life-saving oasis. The research team's dedication to addressing this neglected disease is truly inspiring. Their work reminds us that even in the most challenging of landscapes, there is always hope for progress.

Date :
  1. Date Completed 2020-12-14
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

32293523

DOI: Digital Object Identifier

PMC7158046

Related Literature

Article Analysis
・Effective treatment of chagas disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.